Full Name
Sin Tiong Ong
Ong, S.T.
Main Affiliation


Results 1-15 of 15 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
12014A novel Bcr-Abl-mtor-eIF4a axis regulates IRES-mediated translation of LEF-1Tsai B.P.; Jimenez J.; Lim S. ; Fitzgerald K.D.; Zhang M.; Chuah C.T.H.; Axelrod H.; Nelson L.; Ong S.T. ; Semler B.L.; Waterman M.L.
22017A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancerSoh, S.X; Siddiqui, F.J ; Allen, J.C ; Kim, G.W; Lee, J.C; Yatabe, Y; Soda, M; Mano, H; Soo, R.A ; Chin, T.-M ; Ebi, H; Yano, S; Matsuo, K; Niu, X; Lu, S; Isobe, K; Lee, J.-H; Yang, J.C; Zhao, M; Zhou, C; Lee, J.-K; Lee, S.-H; Lee, J.Y; Ahn, M.-J; Tan, T.J; Tan, D.S ; Tan, E.-H; Ong, S.T ; Lim, W.-T 
319-Jun-2018BIM Deletion Polymorphism Profiling Complements Prognostic Values of Risk Scores in Imatinib-treated Asian Chronic Myeloid Leukemia PatientsHein Than; Weng Kit Lye ; Colin Sng; John Allen, S. ; Tiong Ong ; Charles Chuah 
4Feb-2010Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorJanes, M.R.; Limon, J.J.; So, L.; Chen, J.; Lim, R.J.; Chavez, M.A.; Vu, C.; Lilly, M.B.; Mallya, S.; Ong, S.T. ; Konopleva, M.; Martin, M.B.; Ren, P.; Liu, Y.; Rommel, C.; Fruman, D.A.
52014Identification of cis-acting elements and splicing factors involved in the regulation of BIM pre-mRNA splicingJuan W.C.; Roca X.; Ong S.T. 
62019Identification of drugs for leukaemia differentiation therapy by network pharmacologyEleni G Christodoulou ; Lin Ming Lee ; Kian Leong Lee ; Tsz Kan Fung; Eric So; Enrico Petretto ; S. Tiong Ong ; Owen JL Rackham 
7Oct-2008Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistanceZhang, M.; Fu, W.; Prabhu, S.; Moore, J.C.; Ko, J.; Kim, J.W.; Druker, B.J.; Trapp, V.; Fruehauf, J.; Gram, H.; Fan, H.Y.; Ong, S.T. 
82014Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemiaSoh S.X.; Lim J.Y.S. ; Huang J.W.J.; Jiang N. ; Yeoh A.E.J. ; Ong S.T. 
92017Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotidesLiu, J; Bhadra, M; Sinnakannu, J.R; Yue, W.L; Tan, C.W; Rigo, F; Ong, S.T ; Roca, X
102014Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibitionNg K.P. ; Manjeri A. ; Lee K.L. ; Huang W. ; Tan S.Y. ; Chuah C.T.H. ; Poellinger L. ; Ong S.T. 
112018The arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional targetNg K.P. ; Manjeri A. ; Lee L.M. ; Chan Z.E. ; Tan C.Y.; Tan Q.D. ; Majeed A. ; Lee K.L. ; Chuah C. ; Suda T. ; Ong S.T. 
122014The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsKo T.K. ; Chuah C.T. ; Huang J.W.; Ng K.-P. ; Ong S.T. 
132017The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemiaRauzan M. ; Chuah C.T.H. ; Ko T.K. ; Tiong Ong S. 
142012The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemiaJuan, W.C.; Ong, S.T. 
151-Feb-2022THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair InhibitorsShyamsunder, Pavithra ; Sridharan, Shree Pooja; Madan, Vikas ; Dakle, Pushkar ; Zeya, Cao; Kanojia, Deepika ; Chng, Wee-Joo ; Ong, S Tiong ; Koeffler, H Phillip